2022 Nov 8 -12 SITC 2022 (poster 632)

Clinical Update from a Phase 1, First-in-Human, Open-label Single Agent Study of SUPLEXA Therapeutic Cells in Patients with Metastatic Solid Tumors and Hematologic Malignancies


  • Enrolled heavily pre-treated end-stage oncology population with a variety of tumor types.
  • Excellent safety profile with no drug related adverse events observed to date. All SAEs were classified as not related to SUPLEXA.
  • Encouraging signs of clinical activity in various tumor types, consistent with broad preclinical in vitro activity.
  • Exploratory CyTOF characterization of first 3 patient samples demonstrate
    • Circulating cytokines levels were modulated by SUPLEXA therapeutic cells.
    • SUPLEXA cell manufacturing resulted in similar immune populations.
    • T cells, NK cells and NKT Cells in SUPLEXA showed cytotoxic phenotypes.
    • SUPLEXA cell therapy improved markers of immune health over initial time points.